Defunct Company
Total Trials
10
As Lead Sponsor
6
As Collaborator
4
Total Enrollment
19,814
NCT01047501
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
Phase: Phase 3
Role: Lead Sponsor
Start: Dec 31, 2009
Completion: Feb 28, 2011
NCT01047683
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
Completion: Jul 31, 2011
NCT01492361
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Start: Nov 30, 2011
Completion: May 31, 2018
NCT03885661
Vascepa to Accelerate Lipoprotein Uptake and Elimination
Phase: Phase 1
Role: Collaborator
Start: Jan 11, 2016
Completion: Jun 30, 2021
NCT03697265
A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
Phase: Phase 2
Start: Apr 20, 2018
Completion: Oct 23, 2020
NCT03428477
EPA for Metastasis Trial 2
Start: May 2, 2018
Completion: Apr 30, 2026
NCT04102995
A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine
Start: Aug 27, 2019
Completion: May 15, 2021
NCT04460651
PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial
Start: Aug 14, 2020
Completion: Aug 30, 2021
NCT05434546
A Study to Explore the Effect of Sepranolone in Tourette Syndrome
Start: Feb 16, 2022
Completion: Feb 1, 2023
NCT06637657
Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD
Phase: N/A
Start: Jul 9, 2024
Completion: Jan 31, 2029